Racial differences in clinically localized prostate cancers of black and white men

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 1979-1983

  DeVere White, Ralph W ^a   Deitch, Arline D ^a   Jackson, Aaron G ^a   Gandour Edwards, Regina ^a   Marshalleck, Josephine ^a   Soares, Stephanie E ^a   Toscano, Salvador N ^a   Lunetta, Jennine M ^a   Stewart, Susan Leroy ^a  

^a NONE

Author keywords

Ethnic groups; Genes; P53; Prostatic neoplasms; S phase

Indexed keywords

ARTICLE; CANCER GRADING; CANCER RISK; CAUCASIAN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE; SCORING SYSTEM;

EID: 0032424488     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63216-6     Document Type: Article

References (57)

1. Wingo, P. A., Landis, S. and Ries, L. A.: An adjustment to the 1997 estimate for new prostate cancer cases. CA, 47: 239, 1997.
2. Silverberg, E., Boring, C. C. and Squires, T. S.: Cancer statistics, 1990. CA, 40: 9, 1990.
3. Tribukait, B.: Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application. Eur. Urol., 23: 64, 1993.
4. Majeed, F. A. and Burgess, N. A.: Trends in death rates and registration rates for prostate cancer in England and Wales. Brit. J. Urol., 73: 377, 1994.
5. Brasso, K., Friis, S. and Iverson, P.: Is prostate cancer incidence increasing? J. Urol., part 2, 157: 53, abstract 199, 1997.
6. Nomura, A. M. and Kolonel, L. N.: Prostate cancer: a current prospective. Amer. J. Epidemiol., 13: 200, 1991.
7. Mettlin, C., Jones, G. W. and Murphy, G. P.: Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA, 43: 83, 1993.
8. Boring, C. C., Squires, T. S. and Heath, C. W., Jr.: Cancer statistics for African Americans. CA, 42: 7, 1992.
9. Brawn, P. N., Johnson, E. H., Kuhl, D. L., Riggs, M. W., Speights, V. O., Johnson, C. F., III, Pandya, P. P., Lind, M. L. and Bell, N. F.: Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer, 71: 2569, 1993.
10. Pienta, K. J., Demers, R., Hoff, M., Kau, T. Y., Montie, J. E. and Severson, R. K.: Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987.: Urology, 45: 93, 1995.
11. Morton, R. A., Jr.: Racial differences in adenocarcinoma of the prostate in North American men. Urology, 44: 637, 1994.
12. Ndubuisi, S. C., Kofie, V. Y., Andoh, J. Y. and Schwartz, E. M.: Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology, 46: 71, 1995.
13. Walker, B., Figgs, L. W. and Zahm, S. H.: Differences in the cancer incidence, mortality, and survival between African Americans and whites. Environ. Health Perspect., 103: 275, 1995.
14. Optenberg, S. A., Thompson, I. M., Friedrichs, P., Wojcik, B., Stein, C. R. and Kramer, B.: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. J.A.M.A., 274: 1599, 1995.
15. Moul, J. W., Sesterhenn, I. A., Connelly, R. R., Douglas, T., Srivastava, S., Mostofi, F. K. and McLeod, D. G.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J.A.M.A., 274: 1277, 1995.
16. Freeman, V. L., Leszczak, J. and Cooper, R. S.: Race and the histological grade of prostate cancer. Prostate, 30: 79, 1997.
17. Moul, J. W., Douglas, T. H., McCarthy, W. F. and McLeod, D. G.: Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J. Urol., 155: 1667, 1996.
18. Sakr, W. A., Grignon, D. J., Haas, G. P., Heilbrun, L. K., Pontes, J. E. and Crissman, J. D.: Age and racial distribution of prostatic intraepithelial neoplasia. Eur. Urol., 30: 138, 1996.
19. Whittemore, A. S., Wu, A. H., Kolonel, L. N., John, E. M., Gallagher, R. P., Howe, G. R., West, D. W., Teh, C.-Z. and Stamey, T.: Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Amer. J. Epidemiol., 141: 732, 1995.
20. Whittemore, A. S., Lele, C., Friedman, G. D., Stamey, T., Vogelman, J. H. and Orentreich, N.: Prostate-specific antigen as predictor of prostate cancer in black men and white men. J. Natl. Cancer Inst., 87: 354, 1995.
21. Badalament, R. A., O'Toole, R. V., Young, D. C. and Drago, J. R.: DNA ploidy and prostate-specific antigen as prognostic features in clinically resectable prostate cancer. Cancer, 67: 3014, 1991.
22. Hussain, M. H., Powell, I., Zaki, N., Maciorowski, Z., Sakr, W., KuKuruga, M., Vissher, D., Haas, G. P., Pontes, E. and Ensley, J. F.: Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer. Cancer, 72: 3012, 1993.
23. Ross, R. K., Bernstein, L., Lobo, R. A., Shimuzu, H., Stanczyk, F. Z., Pike, M. C. and Henderson, B. E.: 5-alpha-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet, 339: 887, 1992.
24. Coetzee, G. A. and Ross, R. K.: Re: prostate cancer and the androgen receptor (letter). J. Natl. Cancer Inst., 86: 872, 1994.
25. Irvine, R. A., Yu, M. C., Ross, R. K. and Coetzee, G. A.: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937, 1995.
26. Zhau, H. E., Lian-Sheng, Z., Leland, W. K. C., Bao-Qi, C., Trancoso, P., Chinghai, K., Kojima, M., Symmans, W. F., Ninjia, Z., Palmer, J. L., Mall, J. W., Davis, R., Ming-Fu, Y., Lian-Sheng, X. and Hall, M. C.: Comparative studies of prostate cancers among United States, Chinese and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulation. Urol. Oncol., 1: 51, 1995.
27. Reichardt, J. K., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C. and Ross, R. K.: Genetic variability of the SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973, 1995.
28. Wu, A. H., Whittemore, A. S., Kolonel, L. N., John, E. M., Gallagher, R. P., West, D. W., Hankin, J., Teh, C. Z., Dreon, D. M. and Paffenbarger, R. S., Jr.: Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol., Biomarkers and Prevention, 4: 735, 1995.
29. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511, 1996.
30. Devgan, S. A., Henderson, B. E., Yu, M. C., Shi, C.-Y., Pike, M. C., Ross, R. K. and Reichardt, J. K. V.: Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate, 33: 9, 1997.
31. McIntosh, H.: Why do African-American men suffer more prostate cancer? J. Natl. Cancer Inst., 89: 188, 1997.
32. Hedley, D. W., Friedlander, M. L., Taylor, I. W., Rugg, C. A. and Musgrove, E. A.: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 31: 1333, 1983.
33. Deitch, A. D., Miller, G. J. and deVere White, R. W.: Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue. Cancer, 72: 1692, 1993.
34. Deitch, A. D., Law, H. and deVere White, R.: A stable propidium iodide staining procedure for flow cytometry. J. Histochem. Cytochem., 30: 967, 1982.
35. Deitch, A. D., deVere White, R. W. and Madewell, B. R.: False DNA aneuploidy in canine and human neoplasms. Anticancer Res., 13: 2117, 1993.
36. Wertz, I. E., Deitch, A. D., Gumerlock, P. H., Gandour-Edwards, R., Chi, S.-G. and deVere White, R. W.: Correlation of genetic and immunodetection of TP53 in malignant and benign prostate tissues. Hum. Pathol., 27: 573, 1996.
37. Breslow, N. E. and Day, N. E.: Statistical Methods in Cancer Research, Volume I. Anal. Case-control Studies Publ., 32: 5, 1980.
38. Montgomery, B. T., Nativ, O., Blute, M. L., Farrow, G. M., Myers, R. P., Zincke, H., Therneau, T. M. and Lieber, M. M.: Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch. Surg., 125: 327, 1990.
39. Nativ, O., Winkler, H. Z., Raz, Y., Therneau, T. M., Farrow, G. M., Myers, R. P., Zincke, H. and Lieber, M. M.: Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin. Proc., 64: 911, 1989.
40. Neill, W. A., Norval, M. and Habib, F. K.: Nuclear DNA analysis of prostate tissues: correlation with stage and grade of tumour. Urol. Int., 44: 141, 1989.
41. Greene, D. R., Rogers, E., Wessels, E. C., Wheeler, T. M., Taylor, S. R., Santucci, R. A., Thompson, T. C. and Scardino, P. T.: Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J. Urol., 151: 1301, 1994.
42. Tinari, N., Natoli, C., Angelucci, D., Tenaglia, R., Florentino, B., DiStefano, P., Amatetti, C., Zezza, A., Nicolai, M. and Iacobelli, S.: DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. Cancer, 71: 1289, 1993.
43. Schröder, F., Tribukait, B., Bocking, A., deVere White, R., Koss, L., Lieber, M., Stenkvist, B. and Zetterberg, A.: Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnostic and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand. J. Urol. Nephrol., suppl., 162: 51, 1994.
44. van den Ouden, D., Tribukait, B., Blom, J. H. M., Fossa, S. D., Kurth, K. H., tenKate, F. J. W., Heiden, T., Wang, N., Schroeder, F. H. and the European Organization for Research and Treatment of Cancer Genitourinary Group: Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. J. Urol., 150: 400, 1993.
45. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
46. Murphy, G. P., Busch, C., Abrahamsson, P.-A., Epstein, J. I., McNeal, J. E., Miller, G. J., Mostofi, F. K., Nagle, R. B., Nordling, S., Parkinson, C. and Sesterhenn, I. A.: Histopathology of localized prostate cancer. Consensus Conference on Diagnostic and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand. J. Urol. Nephrol., suppl., 12: 7, 1994.
47. Deshmukh, N. and Foster, C. S.: Grading prostate cancer. In: Pathology of the Prostate. Edited by D. M. Bostwick and C. S. Foster. Philadelphia: W. B. Saunders, pp. 191-227, 1997.
48. Deitch, A. D. and deVere White, R. W.: DNA flow cytometry and immunohistochemistry of p53 pathway genes as predictive modalities in localized prostate cancer. In: Pathology of the Prostate. Edited by D. M. Bostwick and C. S. Foster. Philadelphia: W. B. Saunders, pp. 327-340, 1997.
49. Reed, J. C.: Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1, 1994.
50. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C. and Isaacs, J. T.: Implications of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res., 1: 473, 1995.
51. Brown, C., Sauvageot, J., Kahane, H. and Epstein, J. I.: Cell proliferation and apoptosis in prostate cancer - correlation with pathologic stage? Mod. Path., 9: 205, 1996.
52. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blöchlinger, A., Gasser, T. C. and Mihatsch, M. J.: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Amer. J. Path., 148: 1557, 1996.
53. Moul, J. W., Bettencourt, M.-C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Bauer, J. J.: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159, 1996.
54. Tribukait, B.: Rapid-flow cytometry of prostatic fine needle aspiration biopsies. In: Prognostic Cytometry and Cytopathology of Prostate Cancer. Edited by J. P. Karr, D. S. Coffey and W. Gardner Jr. New York: Elsevier, 1989.
55. Hartwell, L. H. and Kasten, M. B.: Cell cycle control and cancer. Science, 266: 1821, 1994.
56. Jones, E. C., McNeal, J., Bruchovsky, N. and de Jong, G.: DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer, 66: 752, 1990.
57. Stamey, T. A., McNeal, J. E., Freiha, F. S. and Redwine, E.: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol., 139: 1235, 1988.